Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Reiterates Lack of Basis for Mexico’s Ban on…
Seed technology companies comply with Mexico’s biosafety regulations, and Mexico should do the same, BIO said today in its response to the panel set up to determine if Mexico’s ban on imports of genetically modified corn violate its commitments…
Learn more
Biotechnology is a national security Imperative,…
BIO President & CEO John F. Crowley announced today that BIO would take several important steps to reaffirm the organization’s position with regards to national security and the role that the industry plays as a vital strategic asset: “As a…
Learn more
WTO 13th Ministerial Conference outcome "positive…
Following the conclusion of the WTO 13th Ministerial Conference in Abu Dhabi, John Murphy -- BIO's Chief Policy Officer -- made the following statement: “We are encouraged that WTO Members did not agree to extend an intellectual property…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO Encourages Science-based Oversight for Animal and Plant Biotech as Dr. Califf Takes Helm at FDA
February 15, 2022
The following statement may be attributed to BIO's Vice President for Agriculture and Environment Sarah Gallo:  “BIO looks forward to working with a proven leader like Dr. Califf as he takes the helm at FDA. Dr. Califf will lead an…
BIO Statement on Confirmation of Dr. Califf to Lead FDA
February 15, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), made the following statement after Dr. Robert Califf was confirmed by the Senate to lead the Food and Drug Administration (FDA): “We congratulate Dr…
New BIO Report Examines the State of Antibacterial Innovation
February 14, 2022
Current pipeline “insufficient” to meet the threat of AMR, policy reforms critically needed   The Biotechnology Innovation Organization (BIO) today released a new report examining antibacterial innovation and the current pipeline for new…
BIO Stands United with the President's Goal of Ending Cancer
February 2, 2022
The following statement can be attributed to BIO's President and CEO Dr. Michelle McMurry-Heath: “President Biden has long been a champion of research to end cancer. He reaffirmed that commitment today with the relaunch of the "Cancer Moonshot." …
New Report Outlines Best Practices in Bioscience Economic Development Initiatives
January 20, 2022
Today, the Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released a new report on bioscience economic development best practices, “Driving the Bioscience Economy Forward During…
CMS’ Attempt to Restrict Patient Access to Alzheimer’s Drug Sets “Dangerous and Far-Reaching” Precedent
January 13, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to…
"Build Back Better Act" Drug Pricing Provisions Weaken U.S. Innovation Ecosystem, Hurt Patients
November 19, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after the House of Representatives passed the Build Back Better Act: “The legislation that passed the House today…
Patients Empowered with New “Clinical Trials: The Power of Participation” Website
November 16, 2021
The Biotechnology Innovation Organization (BIO) today announced the launch of Clinical Trials: The Power of Participation (CTPoP), a website that addresses how clinical trials work, how to enroll in a clinical trial, and what to expect as a clinical…
White House’s “Build Back Better” Plan Builds New Barriers for Patients and Scientists Discovering Groundbreaking Cures
November 4, 2021
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), made the following statement: "Last week, Democratic leaders announced they had reached a drug pricing “deal.” We wanted to see the details before…
Proposed Prescription Drug User Fee Act VII Performance Goals Letter Earns BIO Support
August 24, 2021
Biotechnology Innovation Organization (BIO) Chief Scientific Officer, E. Cartier Esham issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VII performance goals letter: “The Prescription Drug User Fee…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today